Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy
Overview
Affiliations
Natural killer (NK) cells are endowed with germline-encoded receptors that enable them to detect and kill malignant cells without prior priming. Over the years, overwhelming evidence has identified an essential role for NK cells in tumor immune surveillance. More recently, clinical trials have also highlighted their potential in therapeutic settings. Yet, data show that NK cells can be dysregulated within the tumor microenvironment (TME), rendering them ineffective in eradicating the cancer cells. This has been attributed to immune suppressive factors, including the tumor cells , stromal cells, regulatory T cells, and soluble factors such as reactive oxygen species and cytokines. However, the TME also hosts myeloid cells such as dendritic cells, macrophages, neutrophils, and myeloid-derived suppressor cells that influence NK cell function. Although the NK-myeloid cell crosstalk can promote anti-tumor responses, myeloid cells in the TME often dysregulate NK cells direct cell-to-cell interactions down-regulating key NK cell receptors, depletion of nutrients and growth factors required for NK cell growth, and secretion of metabolites, chemokines and cytokines that ultimately alter NK cell trafficking, survival, and cytotoxicity. Here, we review the complex functions of myeloid-derived cytokines in both supporting and suppressing NK cells in the TME and how NK cell-derived cytokines can influence myeloid subsets. We discuss challenges related to these interactions in unleashing the full potential of endogenous and adoptively infused NK cells. Finally, we present strategies aiming at improving NK cell-based cancer immunotherapies pathways that are involved in the NK-myeloid cell crosstalk in the TME.
Huang Y, Liao H, Luo J, Wei H, Li A, Lu Y Front Oncol. 2025; 14:1502270.
PMID: 39906665 PMC: 11790413. DOI: 10.3389/fonc.2024.1502270.
Hammoud M, Meena C, Dietze R, Hoffmann N, Szymanski W, Finkernagel F Cell Commun Signal. 2024; 22(1):555.
PMID: 39563446 PMC: 11575453. DOI: 10.1186/s12964-024-01940-z.
Chen S, Zhu H, Jounaidi Y Signal Transduct Target Ther. 2024; 9(1):302.
PMID: 39511139 PMC: 11544004. DOI: 10.1038/s41392-024-02005-w.
Ye L, Wang W, Li H, Ji Y, Le X, Xu X Ther Adv Med Oncol. 2024; 16:17588359241290733.
PMID: 39483139 PMC: 11526239. DOI: 10.1177/17588359241290733.
Lacinski R, Dziadowicz S, Melemai V, Fitzpatrick B, Pisquiy J, Heim T Bone Res. 2024; 12(1):55.
PMID: 39333065 PMC: 11436896. DOI: 10.1038/s41413-024-00359-z.